DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Dasatinib
Dasatinib
Management of Chronic Myelogenous Leukemia in Pregnancy
The Effects of Combination Treatments on Drug Resistance in Chronic Myeloid Leukaemia: an Evaluation of the Tyrosine Kinase Inhibitors Axitinib and Asciminib H
Sprycel
Combinatorial Efficacy of Entospletinib and Chemotherapy in Patient-Derived Xenograft Models of Infant Acute Lymphoblastic Leukemia
Antibody–Drug Conjugates: the Last Decade
2021 Formulary List of Covered Prescription Drugs
Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, A
Hypopigmentation of the Skin and Hair Associated with Targetedclinical Therapies and BIOMEDICAL INVESTIGATION
The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer Thomas C
Revisiting Clinical Trials Using EGFR Inhibitor-Based
A Network Medicine Approach for Drug Repurposing in Duchenne Muscular Dystrophy
Ado-Trastuzumab Emtansine: Drug Information
Targeted Therapy–Based Combination Treatment in Rhabdomyosarcoma Anke E.M
Kinase Drug Discovery 20 Years After Imatinib: Progress and Future Directions
Axitinib and Sorafenib Are Potent in Tyrosine Kinase Inhibitor Resistant
2012 NIOSH List of Antineoplastic and Other Hazardous Drugs
Phase II Trial of Dasatinib for Patients with Acquired Resistance To
Bladder Cancer
Top View
Starting on SPRYCEL® (Dasatinib) TABLE of CONTENTS
Tyrosine Kinase Inhibitor Family of Drugs As Prospective Targeted Therapy for COVID-19 Based on in Silico and 3D-Human Vascular Lung Model Studies
1. Gershenson, David.Pptx
Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: a Focus on Transporters and Lysosomal Sequestration
Volume 7 Issue 3
A Case Study of Kinase Inhibitors
Phase Ib Study of Nivolumab and Dasatinib in Patients with Relapsed/Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Pulmonary Arterial Hypertension Associated with Protein Kinase Inhibitors: a Pharmacovigilance- Pharmacodynamic Study
Negative HNSCC – Alteration of EGFR and VEGFR-2 Expression in Vitro
Antibody Conjugation of Nanoparticles As Therapeutics for Breast Cancer Treatment
Efficacy and Safety of Dasatinib with Trastuzumab and Paclitaxel in First Line HER2-Positive Metastatic Breast Cancer: Results from the Phase II GEICAM/2010-04 Study
Gynecomastia in a Male After Dasatinib Treatment for Chronic Myeloid Leukemia
Adult Antiemetic Management of Chemotherapy-Induced Nausea
Survey of Ex Vivo Drug Combination Effects in Chronic Lymphocytic Leukemia Reveals Synergistic Drug Effects and Genetic Dependencies
Alberto Ocaña Hospital Clínico San Carlos Madrid Centro Regional De Investigaciones Biomédicas
Axitinib in Ponatinib-Resistant B-Cell Acute Lymphoblastic Leukemia Harboring a T315L Mutation
Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk
Oncology Agents Policy #: Rx.01.67
Biphasic Mathematical Model of Cell–Drug Interaction That Separates
Nilotinib Shows Prolonged Intracellular Accumulation Upon Pulse-Exposure: a Novel Mechanism for Induction of Apoptosis in CML Cells
Interactions of Tyrosine Kinase Inhibitors with Organic Cation Transporters and Multidrug and Toxic Compound Extrusion Proteins
Dasatinib Promotes ATRA-Induced Differentiation of AML Cells
A Phase I Study of the SRC Kinase Inhibitor Dasatinib with Trastuzumab
Reversible Cardiotoxicity with Tyrosine Kinase Inhibitors
Therapeutic Drug Monitoring and Tyrosine Kinase Inhibitors (Review)
The Tyrosine Kinase Inhibitor Dasatinib (SPRYCEL) Inhibits Chondrocyte Activity and Proliferation
List Item Applications for New Human
Tyrosine Kinase Inhibition in HPV-Related Squamous Cell
203341Orig1s000
XPO1 Inhibitor Approved for Multiple Myeloma
(Sunitinib, Sorafenib, Dasatinib, and Imatinib) on Blood Glucose Levels in Diabetic and Non-Diabetic Patients in General Clinical Practice (Poster) Nicole M
[2016]. NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016
Meta-Analysis of Gastrointestinal Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
Oral Targeted Therapy for Cancer
FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option
SPRYCEL (Dasatinib) Tablets Label
Dasatinib Reversibly Disrupts Endothelial Vascular Integrity By
SPRYCEL® Appropriately
Second Generation Tyrosine Kinase Inhibitors for the Treatment of Chronic Myelogenous Leukaemia with Intolerance of Hematologic Resistance to Imatinib
Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: an Analysis of the FDA Adverse Event Reporting System Database (FAERS)
Emtansine (T-DM1) Resistance in HER2-Positive Cancer
Dasatinib Vs. Imatinib in Patients with Chronic Myeloid Leukemia
European Leukemianet Recommendations for the Management and Avoidance of Adverse Events of Treatment in Chronic Myeloid Leukaemia
Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib
HER2 Splice Variants in Breast Cancer: Investigating Their Impact on Diagnosis and Treatment Outcomes
DRUG NAME: Dasatinib
Comparative Effect of Tyrosine Kinase Inhibitors in Human Cancer Cell Lines
Overview of New Treatments with Immunotherapy for Breast Cancer and a Proposal of a Combination Therapy
Erlotinib Resistance in Lung Cancer Cells Mediated by Integrin B1/Src/Akt-Driven Bypass Signaling
Sprycel, INN-Dasatinib
September 2021 California Advantage Large Group 4 Tier PPO Prescription Drug List
Alternating Or Combined Therapy with Axitinib and Bosutinib for Patients with Chronic Myeloid Leukemia in Chronic, Accelerated Or Blastic Phases 2015-0787
Thyroid Effects of Tyrosine Kinase Inhibitors
Sprycel, INN-Dasatinib
SPRYCEL™ Rx Only
Tyrosine Kinase Inhibitor Associated Vascular Toxicity in Chronic Myeloid